Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMCERE PHARMA

14.020
+0.9807.52%
Volume:13.50M
Turnover:185.80M
Market Cap:36.40B
PE:43.89
High:14.080
Open:13.230
Low:13.230
Close:13.040
52wk High:15.080
52wk Low:6.050
Shares:2.60B
HK Float Shares:2.60B
Volume Ratio:1.89
T/O Rate:0.52%
Dividend:0.18
Dividend Rate:1.25%
EPS(LYR):0.319
ROE:12.45%
ROA:6.50%
PB:4.59
PE(LYR):43.89
PS:4.68

Loading ...

HK Stock Movement | SIMCERE PHARMA (02096) Rises Nearly 6% as IL-2 Mutant Fusion Protein SIM0278 Enters Phase II Clinical Trial

Stock News
·
Yesterday

Simcere Announces Phase II Clinical Trial Launch for SIM0278 in Atopic Dermatitis

Reuters
·
Nov 11

Simcere Launches Phase II Trial of SIM0278 for Moderate-to-Severe Atopic Dermatitis

Reuters
·
Nov 10

Simcere's Il-2 Mutant Fusion Protein Sim0278 Entered Phase Ii Clinical Trial Stage

THOMSON REUTERS
·
Nov 10

Simcere Pharmaceutical (02096) Announces October 2025 Monthly Return

Bulletin Express
·
Nov 05

Global Market Insights: 3 Stocks That May Be Trading Below Estimated Value

Simply Wall St.
·
Nov 04

Hong Kong Market Kicks Off November with Gains in Traditional Sectors; Rotation Strategy Emerges

Stock News
·
Nov 03

Simcere Pharmaceutical Group Limited (2096) Announces Further Revision of 2025 and 2026 Annual Caps

Bulletin Express
·
Oct 20

Simcere Pharmaceutical Revises 2025 and 2026 Annual Caps for Exclusive Promotion Services Agreement

Reuters
·
Oct 20

Evaluating Simcere Pharmaceutical Group (SEHK:2096) Valuation After First U.S. Patient Dosed in Oncology Trial

Simply Wall St.
·
Oct 19

Hong Kong Stocks Movement: SIMCERE PHARMA (02096) Rises Over 4% as First U.S. Patient Enrolled in Phase I Trial of Novel ADC Candidate SIM0505

Stock News
·
Oct 17

BRIEF-NextCure And Simcere Zaiming Announce Expansion Of Ongoing Phase 1 Trial Of SIM0505 Into The US

Reuters
·
Oct 16

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of Sim0505 (Cdh6 ADC) Into the United States

THOMSON REUTERS
·
Oct 16

NextCure Inc - Trial to Accelerate Proof-of-Concept Data in 1H 2026

THOMSON REUTERS
·
Oct 16

Chinese Pharmaceutical Stocks Drop as Investors Take Profit -- Market Talk

Dow Jones
·
Oct 09

Simcere Pharmaceutical Group Ltd. Reports 15.1% Rise in Revenue to RMB3,585 Million for H1 2025; Innovative Pharmaceutical Business Revenue Up 26%

Reuters
·
Sep 29

BOCOM International: Trump's Drug Tariffs Have Limited Impact on Chinese Pharmaceuticals, Recommends Focus on AKESO (09926) and Others

Stock News
·
Sep 29

Nearly Half of Chinese Adults Struggle with Sleep Issues as Pharmaceutical Companies Race to Develop Next-Generation Insomnia Medications

Stock News
·
Sep 22

Simcere Pharmaceutical Group (SEHK:2096) Completes HK$2 Billion Follow-On Equity Offering

Simply Wall St.
·
Sep 12

SIMCERE PHARMA (02096) Completes Placement of Existing Shares and Subscription of New Shares Under General Mandate with "Top-up" Arrangement

Stock News
·
Sep 10